Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma

HTML  Download Download as PDF (Size: 663KB)  PP. 335-341  
DOI: 10.4236/jct.2011.23046    4,986 Downloads   9,164 Views  Citations

Affiliation(s)

.

ABSTRACT

Objective: This study aim to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC) in general clinical practice. Patients and Methods: Non-selected fifty eight Japanese patients with mRCC were treated with sunitinib. Overall survival (OS) and time to treatment failure (TTF) were estimated. Response rate and safety profiles were also assessed. Results: Partial response, stable disease, and progressive disease were observed in 13 (22.4%), 26 (44.8%), and 19 (32.8%) patients, respectively. The median TTF was 5.4 months, and the median OS was 11.2 months. In the prior nephrectomy group, the median TTF was 9.0 months, and the median OS was 16.4 months. In the non-nephrectomy group, the median TTF was 1.1 months, and the median OS was 2.8 months. The most frequently occurring Grade 3/4 adverse events (AEs) were anorexia (17.2%), fatigue (12.1%), thrombocytopenia (13.8%), and anemia (12.1%). Conclusions: Sunitinib has a favorable risk/benefit profile in Japanese mRCC patients with a history of nephrectomy.

Share and Cite:

T. Suyama, T. Ueda, S. Fukasawa, A. Komaru, M. Kobayashi, Y. Naya, N. Nihei and T. Ichikawa, "Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 335-341. doi: 10.4236/jct.2011.23046.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.